Obstetrics & Gynecology Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Obstetrics & Gynecology 2006;107:719-733
© 2006 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME Quiz
Right arrow CME Quiz Answers
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stehman, F. B.
Right arrow Articles by Look, K. Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stehman, F. B.
Right arrow Articles by Look, K. Y.

CLINICAL EXPERT SERIES

Carcinoma of the Vulva

Frederick B. Stehman, MD and Katherine Y. Look, MD

From the Section of Gynecologic Oncology, Department of0 Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, Indiana.

The objective of this review is to summarize the published data about squamous carcinoma of the vulva and to identify promising areas for future investigation. Rather than the routine use of complete radical vulvectomy, a radical wide excision of the vulvar lesion to achieve at least a 1-cm gross margin appears sufficient to treat the primary lesion. A surgical assessment of the groin is required for all patients who have invasion greater than 1 mm. Ipsilateral groin node dissection can be performed through a separate incision. All the nodal tissue medial to the vessels and above the fascia should be removed. Sentinel node evaluation may be a significant step forward, but the false-negative rate is not well enough defined to consider this a standard. Patients with positive inguinal nodes at groin dissection should receive radiation therapy to the ipsilateral groin and hemipelvis. For those patients who have unresectable primary disease or if nodes are palpably suspicious, fixed, and/or ulcerated preoperatively, chemoradiation is the preferred option. Exenterative procedures may rarely be required. Chemotherapy for recurrent or metastatic disease has not been proven to be of value. Although survival rates are high for those with negative nodes, the morbidity associated with standard radical techniques has prompted innovation. Adequately powered trials aimed at further reducing morbidity without compromising survival are underway.




This article has been cited by other articles:


Home page
J. Clin. Pathol.Home page
R Holm, S Knopp, R Kumar, J Lee, J M Nesland, C Trope, and D F Callen
Expression of ZNF652, a novel zinc finger protein, in vulvar carcinomas and its relation to prognosis
J. Clin. Pathol., January 1, 2008; 61(1): 59 - 63.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
R Holm, S Knopp, Z Suo, C Trope, and J M Nesland
Expression of EphA2 and EphrinA-1 in vulvar carcinomas and its relation to prognosis
J. Clin. Pathol., October 1, 2007; 60(10): 1086 - 1091.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American College of Obstetricians and Gynecologists.